Researchers evaluated the associations between time-varying methotrexate use and risk for cardiovascular events in patients with rheumatoid arthritis.
Elderly patients with rheumatoid arthritis (RA) continuously taking methotrexate over the course of 12 months showed a 20% decrease in their risk for cardiovascular events compared with patients who did not take any methotrexate over the previous year, according to a study published in The Journal of Rheumatology.
In this cohort study, researchers examined the effect of time-varying RA treatment on the risk for cardiovascular events in patients older than 66 years. Data on patients, diagnoses, and procedures were taken from Ontario Health Insurance Plan (OHIP) Claims History Database and analyses were limited to patients >66 years with RA for whom there were full prescription drug histories available (n=23,994). Associations between time-varying methotrexate use and time to cardiovascular events, controlling for other risk factors, were found using multivariable Cox regression models. The cumulative duration of methotrexate use over the first year, the previous year, and the entire follow-up period were assessed with alternative models. Investigators also assessed how the strength of these associations may have varied over time.
|Read on: Methotrexate Reduces Cardiovascular Risk in Elderly-Onset Rheumatoid Arthritis|